DNF: A differential network flow method to identify rewiring drivers for gene regulatory networks

Investigators
Qing Nie
Contact info (email)
qnie@uci.edu
1. Define context(s)
reveal new biological insights
Current Conformance Level / Target Conformance Level
Extensive
Primary goal of the model/tool/database

Differential network analysis has become an important approach in identifying driver genes in development and disease. However, most studies capture only local features of the underlying gene-regulatory network topology. These approaches are vulnerable to noise and other changes which mask driver-gene activity. Therefore, methods are urgently needed which can separate the impact of true regulatory elements from stochastic changes and downstream effects. We propose the differential network flow (DNF) method to identify key regulators of progression in development or disease. Given the network representation of consecutive biological states, DNF quantifies the essentiality of each node by differences in the distribution of network flow, which are capable of capturing comprehensive topological differences from local to global feature domains. DNF achieves more accurate driver-gene identification than other state-of-the-art methods when applied to four human datasets from The Cancer Genome Atlas and three single-cell RNA-seq datasets of murine neural and hematopoietic differentiation. Furthermore, we predict key regulators of crosstalk between separate networks underlying both neuronal differentiation and the progression of neurodegenerative disease, among which App is predicted as a driver gene of neural stem cell differentiation. Our method is a new approach for quantifying the essentiality of genes across networks of different biological states.

Biological domain of the model
Identification of driver genes in development and disease from scRNA-seq data
Structure(s) of interest in the model
Driver genes in development and disease
Spatial scales included in the model
cellular to tissue
Time scales included in the model
seconds to weeks
2. Data for building and validating the model
Data for building the model Published? Private? How is credibility checked? Current Conformance Level / Target Conformance Level
in vitro (primary cells cell, lines, etc.)
ex vivo (excised tissues)
in vivo pre-clinical (lower-level organism or small animal) Yes No The model was built in an unsupervised way on unbiased single-cell RNA sequencing data and spatial data. Extensive
in vivo pre-clinical (large animal)
Human subjects/clinical Yes No The model was built in an unsupervised way on unbiased single-cell RNA sequencing data. Extensive
Other: ________________________
Data for validating the model Published? Private? How is credibility checked? Current Conformance Level / Target Conformance Level
in vitro (primary cells cell, lines, etc.)
ex vivo (excised tissues)
in vivo pre-clinical (lower-level organism or small animal) Yes No By comparing to existing knowledge. Adequate
in vivo pre-clinical (large animal)
Human subjects/clinical Yes No By comparing to existing knowledge. Adequate
Other: ________________________
3. Validate within context(s)
Who does it? When does it happen? How is it done? Current Conformance Level / Target Conformance Level
Verification Students/postdocs/investigators Throughout the project The method is verified on simulation datasets. Extensive
Validation Students/postdocs/investigators As the unsupervised model was established The identified driver genes from real data agree well with available knowledge. Extensive
Uncertainty quantification
Sensitivity analysis Students/postdocs/investigators As the unsupervised model was established By tuning key parameters and comparing to annotated data. Adequate
Other:__________
Additional Comments
4. Limitations
Disclaimer statement (explain key limitations) Who needs to know about this disclaimer? How is this disclaimer shared with that audience? Current Conformance Level / Target Conformance Level
Technical noise of scRNA-seq data Scientific community who intends to apply this method to raw scRNA-seq data. In discussion of the paper. Adequate
5. Version control
Current Conformance Level / Target Conformance Level
Extensive
Naming Conventions? Repository? Code Review?
individual modeler Yes N/A Peer
within the lab Yes N/A Peer
collaborators Yes N/A Peer
6. Documentation
Current Conformance Level / Target Conformance Level
Code commented? N/A
Scope and intended use described? N/A
User’s guide? N/A
Developer’s guide? N/A
7. Dissemination
Current Conformance Level / Target Conformance Level
N/A
Target Audience(s): “Inner circle” Scientific community Public
Simulations
Models
Software
Results
Implications of results
8. Independent reviews
Current Conformance Level / Target Conformance Level
Insufficient
Reviewer(s) name & affiliation:
When was review performed?
How was review performed and outcomes of the review?
9. Test competing implementations
Current Conformance Level / Target Conformance Level
Adequate
Yes or No (briefly summarize)
Were competing implementations tested? Yes. The method has been compared to several other state-of-the-art methods for identifying driver genes.
Did this lead to model refinement or improvement? No
10. Conform to standards
Current Conformance Level / Target Conformance Level
Adequate
Yes or No (briefly summarize)
Are there operating procedures, guidelines, or standards for this type of multiscale modeling? Yes. There are several standard procedures for preprocessing scRNA-seq data.
How do your modeling efforts conform? Common data preprocessing procedures are followed.